Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Hohenberger

Showing results (1-10 of 225) with videos related to

Pageof 23
Sort By:
Lancet (London, England)|March 24, 2009
Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?Peter Hohenberger
Nature Clinical Practice. Oncology|March 20, 2008
Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?Peter Hohenberger
The Lancet. Oncology|March 22, 2015
Trabectedin: adding clarification rather than noveltyPeter Hohenberger
The Lancet. Oncology|January 27, 2018
A start towards immunotherapy in sarcomas?Peter Hohenberger
Critical Reviews in Oncology/Hematology|October 10, 2020
The challenge of treating elderly patients with advanced bone and soft tissue sarcomasBernd Kasper, Peter Hohenberger
Cancer|May 21, 2016
Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcomaJens Jakob, Peter Hohenberger
Critical Reviews in Oncology/Hematology|May 12, 2005
Surgical interventions in patients with hematologic malignanciesPeter Hohenberger, Dieter Buchheidt
Annals of Surgical Oncology|May 1, 2019
ASO Author Reflections: Preoperative Pazopanib for High-Risk Soft Tissue Sarcoma: Better Patient Selection is NeededUlrich Ronellenfitsch, Peter Hohenberger
Annals of Surgical Oncology|April 22, 2010
Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST)Peter Hohenberger, Burton Eisenberg
Lancet (London, England)|October 22, 2003
Helicobacter pylori virulence factors--one part of a big pictureMichael Höcker, Peter Hohenberger
Pageof 23

Showing results (1-10 of 225) with videos related to

Sort By:
Pageof 23
Lancet (London, England)|March 24, 2009
Adjuvant imatinib in GIST: a self-fulfilling prophecy, or more?Peter Hohenberger
Nature Clinical Practice. Oncology|March 20, 2008
Should adjuvant imatinib be used as primary treatment for gastrointestinal stromal tumors?Peter Hohenberger
The Lancet. Oncology|March 22, 2015
Trabectedin: adding clarification rather than noveltyPeter Hohenberger
The Lancet. Oncology|January 27, 2018
A start towards immunotherapy in sarcomas?Peter Hohenberger
Critical Reviews in Oncology/Hematology|October 10, 2020
The challenge of treating elderly patients with advanced bone and soft tissue sarcomasBernd Kasper, Peter Hohenberger
Cancer|May 21, 2016
Role of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcomaJens Jakob, Peter Hohenberger
Critical Reviews in Oncology/Hematology|May 12, 2005
Surgical interventions in patients with hematologic malignanciesPeter Hohenberger, Dieter Buchheidt
Annals of Surgical Oncology|May 1, 2019
ASO Author Reflections: Preoperative Pazopanib for High-Risk Soft Tissue Sarcoma: Better Patient Selection is NeededUlrich Ronellenfitsch, Peter Hohenberger
Annals of Surgical Oncology|April 22, 2010
Role of surgery combined with kinase inhibition in the management of gastrointestinal stromal tumor (GIST)Peter Hohenberger, Burton Eisenberg
Lancet (London, England)|October 22, 2003
Helicobacter pylori virulence factors--one part of a big pictureMichael Höcker, Peter Hohenberger
Pageof 23